Chandigarh: Pharma major Venus Remedies today said it will commercially launch its new drug, `Trois`, for treatment of arthritis in June or July to tackle what is predicted to become the "biggest epidemic" in India by 2013 with a USD 672 million market for rheumatoid arthritis drugs.
According to a survey, nearly 70 per cent of people above 65 years of age are suffering from arthritis in India and it would become the biggest epidemic of the country by 2013. The rheumatoid arthritis drug market in India will be more than double by 2013, growing from USD 296 million in 2008 to USD 672 million in 2013. About 1 per cent of the world`s population has rheumatoid arthritis. Its market is expected to exceed USD 23.12 billion by 2015. Arthritis is one of the most chronic health problems in the world and one of the USA`s most common causes of disability. An estimated 46 million adults in the United States that have arthritis and related conditions could benefit from `Trois`. The Panchkula-based company has also been awarded a Gold Medal under DST-Lockheed Martin India`s Innovation Growth Program-2011 for integrated medicinal research product `Trois`. PTI
BJP complains to EC against Rahul Gandhi
Raj Thackeray to support Modi for PM`s post
Star power at play in Lok Sabha polls!
AAP leader Ashwin Upadhyay calls Arvind Kejriwal `CIA agent`